AI assistant
DEXCOM INC — Director's Dealing 2022
Feb 16, 2022
30198_dirs_2022-02-15_ed1c9055-5857-4906-9288-ef20f28832fa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-02-14
Reporting Person: SAYER KEVIN R (Director, Chairman, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-14 | Common Stock | S | 3000 | $418.04 | Disposed | 94617 | Direct |
Footnotes
F1: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.